---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-173988"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:47:11.530441+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q2 Portfolio Receipts +20% to $727M; raises FY 2025 guidance

## Summary
- Portfolio Receipts $727M (+20% YoY); Royalty Receipts $672M (+11%), driven by Voranigo, Trelegy, Evrysdi, Tremfya.
- Raised FY 2025 Portfolio Receipts guidance to $3.05B-$3.15B (was $2.975B-$3.125B).
- Capital deployment of $595M in Q2; $1B in share repurchases in H1 2025 (31M shares).
- Completed acquisition of external manager RP Management in May, making Royalty Pharma an integrated company.
- Entered up to $2B funding arrangement with Revolution Medicines, including $1.25B synthetic royalty on daraxonrasib.

## SEC filing metadata
- accession: 0001193125-25-173988
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312525173988/0001193125-25-173988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312525173988/d90343d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-173988
- JSON: https://secwatch.observer/filing/0001193125-25-173988.json
- Plain text: https://secwatch.observer/filing/0001193125-25-173988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.